Skip to main content

Lunsumio FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 6, 2023.

FDA Approved: Yes (First approved December 22, 2022)
Brand name: Lunsumio
Generic name: mosunetuzumab-axgb
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Follicular Lymphoma

Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager for the treatment of relapsed or refractory follicular lymphoma.

Development timeline for Lunsumio

Dec 22, 2022Approval FDA Approves Lunsumio (mosunetuzumab-axgb) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Dec 12, 2022Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
Jul  5, 2022FDA Grants Priority Review to Genentech’s Mosunetuzumab for People with Relapsed or Refractory Follicular Lymphoma
Dec 11, 2021Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.